Anteris Technologies (ASX:AVR) Advances DurAVR Transcatheter Heart Valve Toward US Pivotal Trial After Strong TAVR Data

Aditi Sarkar

30 October 2026 07:52 PM AEDT

Anteris Technologies (ASX:AVR) Advances DurAVR Transcatheter Heart Valve Toward US Pivotal Trial After Strong TAVR Data

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

DurAVR TAVR system advancing toward IDE pivotal trial application to the US FDA
Positive early feasibility study data demonstrating haemodynamic superiority hypothesis support
Single-piece anatomically correct bovine pericardium design differentiates DurAVR from competitor valves
Global TAVR market exceeds US$3 billion annually, with continued growth as patient eligibility expands

Anteris Technologies Limited (ASX:AVR), trading at A$59.29 as at 30 October 2026, is an Australian medical device company developing the DurAVR Transcatheter Heart Valve System for the treatment of aortic stenosis, a serious and common heart valve disease requiring valve replacement, with the Company advancing toward a US Investigational Device Exemption pivotal trial following compelling early clinical results that support DurAVR's potential to deliver superior haemodynamic performance compared to existing transcatheter valve technologies.

DurAVR: A Differentiated TAVR Technology

Aortic stenosis is the most common valvular heart disease in the developed world, affecting millions of patients over 65 and requiring valve replacement to prevent progression to heart failure and death. Transcatheter aortic valve replacement (TAVR) has revolutionised treatment by allowing valve replacement through a catheter delivered via the femoral artery, avoiding open-heart surgery. However, existing TAVR technologies have design limitations that result in suboptimal haemodynamic performance compared to surgical tissue valves. Anteris's DurAVR is designed differently: it uses a single piece of bovine pericardium shaped to replicate the natural anatomy of the native aortic valve, rather than the multi-component trileaflet designs used by most competitors. Management believes DurAVR's anatomically correct design produces superior blood flow dynamics and better long-term valve performance.

Early Clinical Data: Haemodynamic Performance Results

Anteris has published early clinical data from its DurAVR Early Feasibility Study and CE Mark trial in Europe demonstrating haemodynamic performance metrics that compare favourably to published data for competitor TAVR valves. Key haemodynamic metrics in TAVR include the mean pressure gradient across the valve and the effective orifice area – both of which reflect how efficiently the valve allows blood to flow from the heart into the aorta. DurAVR's clinical data has shown low mean pressure gradients and large effective orifice areas consistent with or better than surgical tissue valve performance benchmarks, which management describes as potentially offering patients a lower long-term risk profile. These data support the hypothesis that DurAVR may deliver superior clinical outcomes versus existing TAVR technologies.

US Pivotal Trial: The Path to FDA Approval

Anteris's primary regulatory objective is to conduct a pivotal clinical trial in the United States to support a Pre-Market Approval (PMA) application to the US Food and Drug Administration. A US IDE (Investigational Device Exemption) application enables a company to conduct clinical trials of a medical device in the US before regulatory approval. Anteris has been engaging with the FDA on the design of its pivotal trial protocol, including the comparator valve to be used, the primary endpoints, and the patient enrolment criteria. US FDA approval is the primary commercial value unlock for Anteris, given that the US TAVR market is the largest in the world. Management has targeted IDE application submission as a near-term milestone.

Market Opportunity and Competitive Landscape

The global TAVR market is valued at more than US$3 billion annually and is growing as the eligible patient population expands following the approval of TAVR in lower surgical risk patients. The market is currently dominated by Edwards Lifesciences (SAPIEN valve family) and Medtronic (Evolut valve family), which together represent the substantial majority of TAVR procedures performed globally. Anteris is positioning DurAVR as a premium TAVR technology with demonstrated haemodynamic advantages, targeting adoption by high-volume structural heart centres seeking the best clinical outcomes for their patients. If DurAVR demonstrates superior outcomes in the pivotal trial, it could achieve a meaningful share of the premium TAVR segment.

FAQs

Q: What is the DurAVR system and what does it treat?

A: DurAVR is Anteris Technologies' transcatheter aortic valve replacement system for treating aortic stenosis, a serious narrowing of the heart's aortic valve that requires replacement to prevent heart failure and death. DurAVR is delivered through a catheter, avoiding open-heart surgery.

Q: What makes DurAVR different from other TAVR valves?

A: DurAVR uses a single piece of bovine pericardium shaped to replicate the natural anatomy of the native aortic valve, producing superior haemodynamic performance compared to the multi-component trileaflet designs used by most competitor valves. Clinical data shows low pressure gradients and large effective orifice areas consistent with surgical valve benchmarks.

Q: What is the next clinical milestone for Anteris Technologies?

A: Anteris's next clinical milestone is the submission of a US IDE (Investigational Device Exemption) application to the FDA, which would allow it to conduct a pivotal clinical trial in the US. A successful pivotal trial would support a PMA application to the FDA for commercial approval.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.